Project Grant R01HL169204
Award Date
9/1/24
Completion Date
8/31/28
Dollars Obligated
$1.2M
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $528,179 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Miami. The grant supports research to investigate whether extracellular vesicles mediate the systemic effects of ischemia training on monocyte reprogramming, and to determine if regulation of the DHCR24 enzyme in myeloid cells impacts limb perfusion, function, and arteriogenesis in peripheral arterial disease. The research...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), aims to advance understanding of the role of endothelial epsins in regulating myocardial ischemia and heart regeneration. The $833,681 award to The Children's Hospital Corporation (Boston Children's Hospital) will fund research to decipher the molecular mechanisms by which targeting cardiac endothelial epsins can enhance...
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, awarded a $156,600 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The University of Texas Southwestern Medical Center (UT Southwestern). The 5-year grant will support research to define the role of the PHF7 protein in driving cardiac reprogramming and improving heart function following a myocardial infarction. Specifically, the project aims to: 1) Characterize...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $243,000 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Cincinnati's Sponsored Research Services Division. The grant will fund a 2-year project to engineer advanced RNA biodevices that leverage CRISPR and ADAR gene-editing technologies. The goal is to improve the efficiency and specificity of converting resident cardiac fibroblasts into functional cardiomyocytes, in order to boost...
This federal Project Grant award of $2,249,307, provided by the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research), aims to study the premature maturation arrest of pluripotent-derived cardiomyocytes (PSC-CMs) and develop strategies to overcome this issue. The project will leverage a high-resolution single cell transcriptome map of endogenous cardiomyocyte maturation to identify a critical gene regulatory network underlying the maturation failure in PSC-CMs....
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $498,991.40 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Arkansas. The grant, effective January 2, 2025 through December 31, 2027, will support the development of microphysiological systems to investigate molecular pathways and cardiomyocyte function in response to hypoxic cardiac injury associated with myocardial infarction and ischemia-reperfusion injury. The project aims to...
This Project Grant award of $601,563 was provided by the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), with a project period from September 1, 2024 to August 31, 2027. The award supports research to investigate the pathogenic roles and molecular mechanisms of the histone lysine demethylases KDM5A and KDM5B in the development and progression of heart failure, with a focus on hereditary cardiomyopathies like Lamin...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $1,398,734 to the University of California, Merced to conduct research on understanding the role of the blood vascular system and endothelial cells in early thymus regeneration after cytotoxic treatments. The project aims to utilize novel intravital imaging techniques to directly analyze the live thymus and characterize the impact...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $549,665 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the University of Maryland, Baltimore to conduct research on "Modulating the Resolution of Angiogenesis and Normalization of the Vasculature for Therapeutic Benefit." The goal is to advance the understanding of the fundamental processes that regulate the resolution of angiogenesis, in order to develop more effective therapeutic approaches for...
This Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $655,636 in funding to the Texas Heart Institute (THI) to investigate the role of cardiac fibroblasts in the development of heart failure in patients with single ventricle congenital heart disease. The objectives are to gain insights into the intrinsic molecular mechanisms that promote cellular senescence, metabolic remodeling, and...